Microplastics are everywhere. Studies detect concentrations up to 1000 particles/L in seawater and up to 10 particles/cm³ in the atmosphere [1]. Humans can be exposed to more than 48,000 microplastic particles/day through inhalation alone [2]. These tiny fragments-smaller than 5 mm–are now in human blood, lungs, placentas, and breast milk [3,4].

Our recent review termed microplastics the "hidden poison"–a phrase reflecting a troubling reality we create daily yet fail to see [5,6]. These particles persist for thousands of years, continuously releasing toxic chemicals throughout their slow degradation [6]. As larger plastics break down into smaller fragments, microplastic concentrations will keep rising for millennia, even if all plastic production stopped today. Critically, this fragmentation process generates nanoplastic-particles <1 μm that exhibit fundamentally different biological behavior and substantially greater toxicity potential than their larger microplastic precursors. We're not just dealing with today's pollution; we're creating a toxic legacy that will accumulate and intensify for generations. While scientists debate their immediate health effects, an urgent connection may be going unrecognized: nanoplastics, more so than microplastics, could be contributing to the global rise in lymphoma.

Research on lymphoma therapeutics has revealed how certain compounds kill cancer through oxidative stress and mitochondrial damage. Nucleoside analogs like gemcitabine, fludarabine, and cladribine induce lymphoma cell death through rapid reactive oxygen species (ROS) generation that overwhelms mitochondrial defenses [7,8]. Our laboratory work with FNC (2′-deoxy-2′-β-fluoro-4′-azidocytidine, also known as Azvudine) demonstrated similar mechanisms–when cancer cells experience intense, sudden stress, a burst of ROS flooding their mitochondria triggers death [9–11]. That's how treatment works.

Recent work on environmental toxins, particularly micro- and nanoplastics, has uncovered something striking. Multiple research groups have shown that these plastic particles trigger the same mechanisms–ROS generation, mitochondrial dysfunction, inflammation–but differently [12–15]. Instead of an intense burst that kills cells, plastic particles create chronic, low-level stress over years. Nanoplastics, with their ability to penetrate cells and reach mitochondria directly, may exert these effects more potently than larger microplastics that remain primarily extracellular [16]. Same pathways, opposite outcome: instead of killing cancer, this chronic stress may cause it [6].

The toxicological principle is well-established: the dose makes poison [17]. A sudden, high dose of ROS kills lymphoma cells therapeutically. Chronic, low doses may promote cancer through accumulated DNA damage [18]. However, critical gaps exist: Most studies use concentrations potentially exceeding human tissue exposures, and exposure durations fall far short of decades-long human exposures. Whether environmentally relevant micro- and nanoplastic concentrations induce sufficient stress to promote lymphomagenesis over human lifespans remains unknown.

While microplastics (1 μm–5 mm) dominate discussions in community nowadays, nanoplastics (<1 μm, particularly <100 nm) may represent the primary biological threat due to fundamentally different properties. This size-dependent toxicity mirrors established nanotoxicology principles [19,20].

Enhanced blood entry

Particles <200nm cross epithelial and endothelial barriers through transcytosis with exponentially greater efficiency than microplastics [21,22]. Specialized gut cells preferentially transport particles 50–100 nm [23]. This means nanoplastics achieve systemic distribution while most microplastics remain in the gastrointestinal tract.

Cellular penetration

Nanoplastics enter cells via endocytosis, reaching mitochondria and nuclei-sites of direct molecular damage [16]. Microplastics remain largely extracellular. This intracellular access dramatically amplifies nanoplastic toxicity potential.

Lymphoid accumulation

Biodistribution studies show nanoparticles accumulate preferentially in spleen and lymph nodes at 4–8-fold higher concentrations than other organs [23,24]. This lymphoid tropism makes nanoplastics particularly relevant to lymphoma etiology.

The continuum matters

Microplastics continuously fragment into nanoplastics through environmental weathering [25]. Environmental microplastics serve as persistent reservoirs generating escalating nanoplastic exposure over time. This means nanoplastic concentrations will continue rising for centuries even if plastic production ceased today.

Critical limitation

Current analytical methods cannot reliably detect nanoplastics <500 nm–precisely the size fraction with potentially greatest toxicity [26]. True human nanoplastic burdens remain essentially unknown, meaning we may be dramatically underestimating actual exposure levels.

Once micro- and nanoplastics cross into the bloodstream-and evidence confirms they do [3,4]–where do they accumulate? Basic anatomy suggests: lymph nodes. Given nanoplastics' superior vascular translocation capacity, they likely reach and accumulate in lymph nodes more efficiently than larger microplastics.

Lymph nodes are biological filters designed to trap foreign particles and activate immune responses [27]. Blood flows through them constantly. If plastic particles circulate in blood, anatomical logic predicts they should concentrate in lymph nodes. And here's the critical point: lymph nodes are where most lymphomas begin [28].

Consider other cancers where microplastic exposure has been directly linked to cancer development: Studies demonstrate that microplastic exposure promotes lung cancer through oxidative stress, inflammation, and epithelial-mesenchymal transition (EMT) pathways [29,30]. Microplastics detected in lung tissues show associations with increased cancer biomarkers and inflammatory responses [31,32]. For gastrointestinal cancers, research links microplastic exposure to colorectal cancer development through gut microbiota disruption, chronic inflammation, and direct genotoxicity [12,33], with higher microplastic concentrations detected in cancerous colon tissues compared to healthy tissues [34]. Skin cancer risk increases with dermal microplastic exposure through UV-induced degradation of plastic particles that generate reactive oxygen species and promote melanoma cell proliferation [35,36]. While these associations do not establish definitive causation-cancer development involves multiple factors including genetics, chronic inflammation, and other environmental exposures-the pattern is compelling: cancer appears where plastic particles accumulate and exert chronic toxic effects. Microplastics may be one of several environmental factors contributing to carcinogenesis, not the sole cause. Nanoplastics' enhanced tissue penetration and preferential lymphoid accumulation make them particularly concerning for lymphoma development. Yet remarkably, despite clear links between microplastic exposure and lung, skin, and gastrointestinal cancers, no published studies have investigated whether micro- or nanoplastics collect in lymph nodes or examined their role in lymphoma specifically. This represents a critical gap requiring urgent investigation, particularly given that lymph nodes–unlike solid organs where plastic-cancer links have been established–are designed specifically to filter and trap circulating particles.

Our comprehensive mechanistic review systematically examined how microplastics may affect pathways known to cause lymphoma [6]. While we hypothesized that microplastics could activate these pathways, nanoplastics also appear more biologically plausible as primary drivers due to their superior bioavailability and cellular access. The evidence suggests plastic particles can activate all five canonical pathways:

1. Chronic inflammation: Micro- and nanoplastics activate immune signaling, releasing inflammatory molecules like IL-6 and TNF-α [14,15]. They also activate NLRP3 inflammasome, releasing cytokines that support lymphoma cell proliferation [37]. This persistent inflammation resembles conditions driving lymphomas through chronic bacterial infections [38]. Nanoplastics' ability to penetrate immune cells directly may trigger more potent inflammatory responses than extracellular microplastics.

2. Oxidative stress: While our laboratory demonstrated that intense oxidative stress kills lymphoma cells therapeutically [10,11], plastic particles produce the opposite-mild oxidative stress continuously, damaging DNA slowly over time rather than destroying cells outright [12,13]. Nanoplastics' mitochondrial localization enables direct ROS generation at the source, potentially explaining their greater genotoxic potential compared to microplastics. The difference resembles a knockout punch versus slow poisoning.

3. Immune system disruption: Studies show plastic particle exposure alters T-cell and B-cell function, reduces NK cell activity by ~40%, and promotes T-cell exhaustion through immune checkpoint upregulation [39–41]. The result: reduced cancer protection combined with increased lymphocyte division-precisely the wrong combination. Nanoplastics' systemic distribution and lymphoid accumulation suggest they may drive these immune disruptions more effectively than microplastics.

4. DNA damage: Plastic particles induce chromosomal aberrations, micronucleus formation, and oncogenic translocations [42]. They also cause epigenetic modifications including DNA methylation changes affecting lymphocyte development [43,44]. As vectors for environmental toxicants, plastic particles deliver additional genotoxic compounds to tissues. Nanoplastics' nuclear penetration capacity enables direct DNA interaction, potentially explaining observations of enhanced genotoxicity with smaller particle sizes.

5. Hormone disruption: Plastic-associated chemicals like BPA and phthalates activate estrogen receptors and JAK/STAT signaling, promoting lymphocyte proliferation and inhibiting apoptosis through Bcl-2 overexpression [45,46]. Nanoplastics' greater surface-area-to-mass ratio amplifies chemical leaching, potentially intensifying endocrine disruption compared to larger microplastics.

The logic appears straightforward: Lymphoma develops through pathways A, B, C, D, and E. Micro- and nanoplastics activate pathways A, B, C, D, and E. Nanoplastics activate these pathways more efficiently due to enhanced bioavailability and cellular penetration. Therefore, nanoplastics and microplastics represent a plausible contributing factor worthy of urgent investigation.

However, critical gaps prevent definitive conclusions: Most data derive from non-lymphoid tissues at supraphysiological concentrations. No studies demonstrate that human exposure levels simultaneously activate all five pathways in lymphoid tissues specifically. Crucially, no studies have systematically compared the effects of size-fractionated particles (e.g., 10 μm microplastics vs. 100 nm nanoplastics) on lymphocyte biology. No mechanistic studies link pathway activation to actual malignant transformation in lymphocytes.

If plastic particles circulate in blood and evidence confirms they do [3,4,47]–why might they affect lymphoma risk more than leukemia (blood cancer originating in bone marrow)? The answer may lie in anatomy. Lymph nodes receive massive blood flow and actively filter particles–creating maximum exposure [27,48]. Bone marrow receives lower blood flow and is partially protected by the blood-marrow barrier [49]. This exposure gradient predicts lymphoma risk should exceed leukemia risk if plastics contribute to hematologic malignancy. Nanoplastics' preferential accumulation in lymphoid tissues rather than bone marrow further supports this anatomical hypothesis.

However, this requires evidence. No studies have compared micro- or nanoplastic concentrations in lymph nodes versus bone marrow. No epidemiological studies have examined whether plastic exposure shows differential associations with lymphoma versus leukemia risk.

For clinicians: Lymphoma patient assessments could include environmental exposure histories–occupation, diet, plastic product use. Environmental factors deserve systematic documentation for future research.

For researchers: Several urgent questions demand investigation:

• Case-control studies comparing size-fractionated microplastic and nanoplastic concentrations between lymphoma patients and healthy controls, with particular emphasis on measuring the nanoplastic fraction currently invisible to most analytical methods

• Direct measurements of plastic particle concentrations in lymph node biopsies from lymphoma patients and controls, using advanced techniques capable of detecting nanoplastics <500 nm

• Animal studies testing whether chronic exposure to size-fractionated particles (comparing microplastics vs. nanoplastics) at environmentally relevant concentrations increases lymphoma incidence

• Mechanistic investigations examining whether chronic low-dose nanoplastic exposure induces cellular dysfunction at levels that promote rather than prevent malignancy, testing the hypothesis that nanoplastics exhibit greater lymphomagenic potential than microplastics due to enhanced cellular penetration.

For public health: Historical precedents exist. Asbestos regulation reduced mesothelioma. Smoking reduction lowered lung cancer rates [50]. If micro- and nanoplastics significantly contribute to lymphoma risk, this could represent preventable cancer amenable to policy intervention.

Unlike most toxins, microplastics never break down. They persist for centuries [49,51]. Humans inhale over 48,000 particles daily [2]. Infants are born with microplastics already in their bodies [4]. Every year of delay means more plastic accumulates in human tissues. Moreover, as microplastics fragment into nanoplastics through environmental weathering, their toxicity potential increases exponentially while environmental concentrations escalate-meaning the biological threat intensifies over time even as total polymer mass remains constant.

Society didn't wait for absolute proof before regulating asbestos or tobacco. Action came from strong evidence and plausible mechanisms [52]. The nanoplastic-lymphoma hypothesis-while unproven-merits serious investigation given universal exposure, rising lymphoma incidence, anatomical logic, and mechanistic coherence across established lymphoma pathways. This commentary proposes a testable hypothesis requiring urgent investigation, not a proven causal relationship. The precautionary principle suggests that when a plausible mechanism exists alongside universal exposure and rising disease rates, investigation should not await definitive proof-particularly for a contaminant that will persist and accumulate for centuries regardless of future regulatory action.

The research journey from lymphoma therapeutics to environmental toxicology has revealed a thought-provoking possibility: the cellular mechanisms exploited for therapy may mirror those that environmental plastics exploit to promote disease. Medicine may be treating lymphoma while overlooking significant environmental contributors to its rising incidence.

This hypothesis demands urgent testing. If nanoplastics prove to be significant contributors, humanity may face a preventable cancer epidemic that grows with every plastic product manufactured-not because of the total plastic mass produced, but because of the invisible nanoplastic particles continuously generated as environmental plastics fragment. The plastic consumed this week might be more than pollution–it could represent a long-term health hazard we're only beginning to recognize.

The question isn't whether there's enough evidence to prove causation-there isn't. The question is whether the mechanistic plausibility, anatomical logic, universal exposure, and potential public health implications justify immediate, well-funded investigation. Given that nanoplastics combine universal human exposure with enhanced bioavailability, cellular penetration, and lymphoid accumulation-all properties absent in larger microplastics–the answer appears clear: this hypothesis warrants rigorous scientific testing through the research priorities outlined above, with particular emphasis on size-fractionated analyses that can distinguish microplastic from nanoplastic effects.

The author declares no competing interests.

I thank anonymous peer reviewers for constructive feedback that substantially improved this commentary.